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Abstract
Thyroid dysfunction (TD) frequently occurs as an autoim-
mune complication of immune reconstitution therapy (IRT), 
especially in individuals with multiple sclerosis treated with 
alemtuzumab, a pan-lymphocyte depleting drug with subse-
quent recovery of immune cell numbers. Less frequently, TD 
is triggered by highly active antiretroviral therapy (HAART) in 
patients infected with human immunodeficiency virus (HIV), 
or patients undergoing bone-marrow/hematopoietic-stem-
cell transplantation (BMT/HSCT). In both alemtuzumab-in-
duced TD and HIV/HAART patients, the commonest disorder 
is Graves’ disease (GD), followed by hypothyroidism and thy-
roiditis; Graves’ orbitopathy is observed in some GD patients. 
On the contrary, GD is rare post-BMT/HSCT, where hypothy-
roidism predominates probably as a consequence of the as-
sociated radiation damage. In alemtuzumab-induced TD, the 
autoantibodies against the thyrotropin receptor (TRAb) play 
a major role, and 2 main aspects distinguish this condition 
from the spontaneous form: (1) up to 20% of GD cases ex-
hibit a fluctuating course, with alternating phases of hyper- 
and hypothyroidism, due to the coexistence of TRAb with 
stimulating and blocking function; (2) TRAb are also positive 
in about 70% of hypothyroid patients, with blocking TRAb 
responsible for nearly half of the cases. The present guide-
lines will provide up-to-date recommendations and sugges-
tions dedicated to all phases of IRT-induced TD: (1) screening 
before IRT (recommendations 1–3); (2) monitoring during/
after IRT (recommendations 4–7); (3) management of TD 
post-IRT (recommendations 8–17). The clinical management 
of IRT-induced TD, and in particular GD, can be challenging. 
In these guidelines, we propose a summary algorithm which 
has particular utility for nonspecialist physicians and which is 
tailored toward management of alemtuzumab-induced TD. 
However, we recommend prompt referral to specialist endo-
crinology services following diagnosis of any IRT-induced TD 
diagnosis, and in particular for pregnant women and those 
considering pregnancy. © 2019 The Author(s) 
Published by S. Karger AG, Basel
This article is licensed under the Creative Commons Attribution-
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Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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Introduction
Thyroid dysfunction (TD) is a common side effect of 
many treatments acting with different mechanisms, in-
cluding but not limited to interferon alpha [1], interleu-
kin-2 [2], thalidomide [3], amiodarone [4], radiation 
therapy [5], lithium [6], bexarotene [7], immune check-
point inhibitors [8], and thyrosine kinases inhibitors [9, 
10]. The present guidelines will focus on thyroid autoim-
munity (TA) induced by immune reconstitution therapy 
(IRT), characterized by a recovery of immune cell num-
bers following a depletion phase, which to date has been 
reported in 3 settings: (1) following alemtuzumab (Lem-
trada) treatment for active relapsing remitting multiple 
sclerosis (MS); (2) after treatment of human immunode-
ficiency virus (HIV) infected patients with highly active 
antiretroviral therapy (HAART); (3) following allogeneic 
bone marrow transplantation (BMT) or hematopoietic 
stem cell transplantation (HSCT) [11]. IRT-induced TA 
has a late and variable onset, typically occurring 16–23 
months after the last alemtuzumab treatment for MS [12–
14], 8–33 months after the commencement of HAART in 
HIV patients [15–21], and 2.5–4.3 years post BMT [22].
T cells are mainly involved in autoimmunity induced 
by IRT, since this phenomenon has not been described 
following treatment with B-cell-only depleting agents 
such as rituximab [23, 24]. Alemtuzumab is a humanized 
monoclonal antibody targeting CD52; for the treatment 
of relapsing remitting MS it is given intravenously as 2 
cycles 12 months apart (with additional cycles triggered 
by clinical or radiological evidence of disease), without 
additional long-term immunosuppressive drugs. Alem-
tuzumab causes transient depletion of both B and T lym-
phocytes (pan-lymphopenia) with an ensuing reconstitu-
tion phase characterized by a quick and complete recov-
ery of B lymphocyte numbers (6–12 months) [25], versus 
a slower and partial recovery of CD4/CD8 T lymphocytes 
[26, 27]. Similarly, HIV-infected patients have low CD4 
T cell numbers that increase following HAART [28]. Sec-
ondary autoimmunity following allogeneic BMT/HSCT 
arises by additional mechanisms distinguishing it from 
the other IRTs including: (1) adoptive immunity, that is 
transferral of autoreactive lymphocyte clones from the 
donor to the recipient and (2) graft-versus-host disease 
with the loss of regulation of autoreactive T lymphocytes 
previously kept under control by peripheral immune tol-
erance [11, 29].
TA can also occur as a complication of alemtuzumab 
treatment administered for other autoimmune disorders, 
such as vasculitis (11% prevalence) [30] and Beçhet’s dis-
ease (25% prevalence) [31]. However, reliable data to de-
termine incidence and clinical features of TA in these cir-
cumstances remain limited. Interestingly, TA has been 
described only rarely when alemtuzumab is administered 
for rheumatoid arthritis [32], blood cancers [33], or trans-
plantation [34], suggesting a disease specific and/or ge-
netic background effect. There is a single-case report of 
Graves’ disease (GD) 4 years after alemtuzumab induc-
tion for renal transplantation [35]. However, additional 
possible reasons for this include the use of alternate treat-
ment regimens and frequent combination with the long-
term use of other immunosuppressive drugs [32, 33, 36]. 
It is noteworthy that in the phase 2 trial of alemtuzumab 
as a treatment of relapsing remitting MS, TD rates were 
higher in patients treated with a daily dose of 12 mg ver-
sus those treated with 24 mg (39 vs. 29%, Fisher’s exact 
test, p = 0.015) [13]. For the reasons outlined above, these 
guidelines will therefore predominantly refer to TA in-
duced by alemtuzumab in the context of MS treatment, 
or HIV/HAART. Note that BMT/HSCT will not be dis-
cussed in detail since mainly associated with thyroid dis-
orders, including TA, secondary to the irradiation of the 
thyroid gland, and are unlikely related to the immune re-
constitution alone.
TA caused by IRT is predominantly humoral, induc-
ing a rise of both thyroid-stimulating hormone receptor 
(TSHR) autoantibodies (TRAb) and autoantibodies to 
thyroid peroxidase (TPOAb) [13, 17]; in particular, GD 
is the most common manifestation [14]. Recent studies 
have demonstrated that TRAb with TSHR-blocking ac-
tivity (TBAb) are responsible for 30–50% of all cases of 
IRT-induced hypothyroidism [12, 37], which differs from 
the spontaneous form of autoimmune hypothyroidism 
where TBAb account for only 10% of cases [38, 39]. The 
frequency of secondary TA among MS patients treated 
with alemtuzumab in clinical trials has been reported as 
between 34 [13] and 41% [12, 14], of which 63 [14] – 5% 
[13] are cases of GD, 21 [13] – 34% [14] hypothyroidism, 
and 3 [14] – 12% [13] subacute/transient thyroiditis.
TA occurring in HIV/HAART patients is less com-
mon, with a GD incidence of 3.0% in women and 0.2% in 
men [15], representing a 1.5–2 fold increase compared 
with the general population [40]. A higher (4-fold) fre-
quency has been noted among black Africans [15, 21]. The 
spectrum of TA following HIV/HAART is reported as 
around 88% GD, 6% Hashimoto’s thyroiditis, and 6% hy-
pothyroidism (negative for thyroid autoantibodies) [15].
Following allogeneic BMT/HSCT subclinical or clini-
cal hypothyroidism occurs in 9–30% of cases, mainly re-
lated to radiation to the thyroid gland during the prepar-
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ative regimens [41–43]. Post-BMT/HSCT GD cases are 
rare and in most cases caused by adoptive immunity [44–
47].
Online supplementary Table 1 (for all online suppl. 
material, see www.karger.com/doi/10.1159/000500881) 
lists the main definitions and abbreviations used.
Methods
The taskforce for these guidelines was instituted by the execu-
tive committee of the European Thyroid Association (ETA). Ref-
erences were searched in PubMed using the following search 
terms: IRT, secondary TA, alemtuzumab, HIV/HAART, BMT/
HSCT, GD. The Grading of Recommendations Assessment, De-
velopment and Evaluation system was used to grade the quality of 
evidence and the strength of recommendations [48, 49]. It consists 
of 2 scorings, namely, quality of evidence (∅○○○ = very low; 
∅∅○○ = low; ∅∅∅○ = moderate, and ∅∅∅∅ = high) and 
strength of recommendation (1 = strong, associated with the 
phrase “we recommend”; 2 = weak, associated with the phrase “we 
suggest”). The draft guidelines were discussed by the members of 
the task force and then posted on the ETA website for 4 weeks to 
receive comments from the ETA members.
A summary of the recommendations is presented in Table 1.
1. Baseline Thyroid Function Should Be Screened before IRT? 
What Are the Contraindications to IRT?
Around one-third of patients with no previous history of thy-
roid disorders will develop TD following alemtuzumab [12–14]; 
therefore, it is important to assess their baseline thyroid function. 
Small independent studies have suggested that the risk of TD is 
increased in subjects with established TA [13, 37]. Where thy-
roidectomy or radioiodine (RAI) ablation has been performed 
for GD the risk of recurrence would be expected to be low. How-
ever, caution is advised in patients with GD in remission after 
previous medical therapy, and also those with previous lympho-
cytic (autoimmune) or post-partum thyroiditis. In patients on 
thyroid hormone replacement for hypothyroidism, caution is 
also advised as fluctuation in the autoimmune state and thyroid 
status is possible; there is currently no evidence to quantify this 
risk.
Recommendations
1a. We recommend the measurement of thyroid-stimulating 
hormone (TSH) in all subjects before IRT. Free-thyroxine (FT4), 
and free-triiodothyronine (FT3) if available, should be measured 
where TSH is abnormal (1, ∅∅○○).
1b. Baseline or previous TD is not a contraindication to initia-
tion or repeated treatment with IRT. In cases of previous/baseline 
GD in remission or autoimmune hypothyroidism or post-partum 
thyroiditis, we recommend close monitoring by an endocrinolo-
gist with investigation and treatment (if necessary) before IRT (1, 
∅∅○○).
1c. Active thyroid eye disease and cardiac disease where thyro-
toxicosis would be a significant risk should be considered contra-
indications to IRT; we recommend controlling/treating these con-
ditions before IRT (1, ∅○○○).
2. Should Thyroid Autoantibodies (TPOAb and TRAb) Be 
Tested before IRT?
In one study, 69% of MS patients who had positive TPOAb be-
fore receiving alemtuzumab developed TD, compared to 31% of 
those with negative TPOAb. However, the number of patients with 
baseline positive TPOAb levels was small (n = 16), and 85% of 
those developing TD were TPOAb negative at baseline [13]. Hence, 
while pretreatment TPOAb levels may help to identify patients at 
particular risk of post-alemtuzumab TD, a surveillance program 
directed at only these individuals would not detect the majority 
of TD.
Similarly, TRAb measured with published specialized in-house 
assays, but not standard clinical automated assays, have been de-
tected at baseline in about one-third of patients that will later de-
velop TD, with a similar predictive role to TPOAb [37]. No data 
support the routine TRAb measurement using standard commer-
cial assays before commencement of alemtuzumab; where checked 
it was almost uniformly negative, and if positive, patients often did 
not receive the study drug [13, 50].
The value of baseline antithyroid antibody levels before alem-
tuzumab treatment for indications other than MS has not been 
studied [30].
Recommendation
2. We do not suggest routine measurement of TPOAb or TRAb 
before IRT, although the TD risk is increased in thyroid-autoanti-
body positive patients (2, ∅∅○○).
3. Should Thyroid Imaging Be Performed before IRT?
Thyroid scintigraphy is only indicated before IRT in case of low 
TSH levels associated with negative TRAb and/or nodularity [51–
53].
Recommendation
3. We do not recommend routine thyroid ultrasound or scin-
tigraphy scans before IRT (1,∅∅∅○).
4. Which Thyroid Function Test(s) Should Be Used to Assess 
Thyroid Status after IRT?
The commonest TD occurring post-alemtuzumab and in HIV/
HAART patients is GD, followed by hypothyroidism and thyroid-
itis [12, 13, 15]. GD is rare post-BMT/HSCT [44–47], where hypo-
thyroidism predominates [41–43]. In all of these conditions, a 
change in TSH levels is the earliest abnormality identified on thy-
roid function testing.
Recommendations
4a. We recommend TSH testing to assess for post-IRT TD. De-
pending on local resources, FT4 may be also routinely measured 
(1, ∅∅∅○).
4b. We recommend repeat TSH testing within 1 month if the 
TSH level is low (0.10–0.39 mU/L; 1, ∅∅○○).
4c. We recommend repeat TSH testing within 2 weeks togeth-
er with FT4 if TSH is elevated, and with FT4 and FT3 if TSH is 
suppressed (< 0.10 mU/L). A full history and examination should 
also be performed, focusing on thyroid signs, symptoms, and con-
tributing factors (1, ∅∅∅○).
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Table 1. Recommendations
Recommendation Comments Strength/level 
of evidence
Recommendations before IRT (recommendations 1–3)
1. Baseline thyroid function should be 
screened before IRT? What are the 
contraindications to IRT?
1a. We recommend TSH measurement in all subjects before IRT; FT4 (FT3 if available) 
should be measured where TSH is abnormal
1, ∅∅○○
1b. Baseline or previous TD is not a contraindication to initiation or repeated treatment 
with IRT; in cases of previous/baseline GD in remission or autoimmune 
hypothyroidism or post-partum thyroiditis, we recommend close monitoring by an 
endocrinologist with investigation and treatment (if necessary) before IRT
1, ∅∅○○
1c. Active thyroid eye disease and cardiac disease where thyrotoxicosis would be a 
significant risk are contra-indications to IRT; we recommend controlling/treating these 
conditions before IRT
1, ∅○○○
2. Should thyroid autoantibodies (TPOAb 
and TRAb) be tested before IRT?
2. We do not suggest routine measurement of TPOAb or TRAb before IRT, although 
the TD risk is increased in thyroid-autoantibody positive patients
2, ∅∅○○
3. Should thyroid imaging be performed 
before IRT?
3. We do not recommend routine thyroid ultrasound or scintigraphy scans before IRT 1, ∅∅∅○
Monitoring of patients receiving IRT (recommendations 4–7)
4. Which thyroid function test(s) should be 
used to assess thyroid status after IRT?
4a. We recommend TSH testing to assess for post-IRT TD; depending on local 
resources, FT4 may be also routinely measured
1, ∅∅∅○
4b. We recommend repeat TSH testing within 1 month if the TSH level is low (0.10–
0.39 mU/L)
1, ∅∅○○
4c. We recommend repeat TSH testing within 2 weeks together with FT4 if TSH is 
elevated, and with FT4 and FT3 if TSH is suppressed (<0.10 mU/L); a full history and 
examination should also be performed, focusing on thyroid signs, symptoms, and 
contributing factors
1, ∅∅∅○
5. How frequently should thyroid function 
be tested after IRT?
5a. Following alemtuzumab, we recommend instituting biochemical follow-up with 
TSH testing every 3 months (Fig. 1); time points should not be missed, as TD can 
develop rapidly; therefore, efforts should be made to ensure patients do not miss 
appointments
1, ∅∅○○
5b. We recommend advising IRT patients to alert the medical team if they develop 
signs and symptoms of TD, that is, excessive sweating, unexplained weight loss or gain, 
nervousness, tachycardia, and worsening tiredness
1, ∅∅○○
5c. We do not recommend routine TSH monitoring following HAART in HIV patients; 
TSH measurement should be performed if TD is suspected on clinical grounds
1, ∅∅○○
5d. We suggest to manage the long-term follow-up of patients after BMT/HSCT within 
a dedicated specialized setting
2, ∅○○○
6. For how long post-IRT routine thyroid 
function testing should be performed?
6a. We recommend routine 3 monthly measuring of thyroid function to be continued 
for 4 years from the last alemtuzumab treatment (Fig. 1)
1, ∅∅○○
6b. After this period, testing should be performed based on symptoms and signs 
suggestive of TD
1, ∅∅○○
7. Should thyroid autoantibodies be 
measured in euthyroid individuals during 
routine monitoring for TD following IRT?
7. We do not recommend routine measurement of thyroid autoantibodies in euthyroid 
patients during surveillance
1, ∅○○○
Management and referral of patients who develop post-IRT TD (recommendations 8–17)
8. Should patients be routinely screened 
with thyroid imaging post IRT?
8. We do not recommend routine thyroid ultrasound or scintigraphy post IRT 1,∅∅∅○
9. When should patients with post-IRT TD 
be referred to an endocrinologist?
9a. We recommend referral to and review by an endocrinologist within 2–4 weeks in 
case of abnormal thyroid function confirmed on repeat testing, including asymptomatic 
cases
1, ∅○○○
9b. Depending on the local organization of clinical services, we suggest the use of a 
clinical thyroid management algorithm developed for nonspecialist physicians and 
based on alemtuzumab-induced TD (Fig. 2); however, this should be combined with 
the availability of an endocrinologist in case of urgent thyroid-related problems or a 
complicated disease course
2, ∅○○○
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Table 1 (continued)
Recommendation Comments Strength/level 
of evidence
10. What are the recommendations for 
pregnant patients or patients planning 
pregnancy?
10a. We suggest that the thyroid function of women pregnant or seeking pregnancy 
within 4 years of last IRT should be monitored more frequently (i.e., monthly)
2, ∅○○○
10b. According to local resources and services, we suggest that these women should be 
immediately referred to an endocrinologist as soon as they develop TD, to be 
commenced on appropriate thyroid treatment and monitoring during pregnancy in a 
specialist setting
2, ∅○○○
11. What investigation should be performed 
in patients found to have post-IRT 
biochemical thyrotoxicosis?
11. If biochemistry is consistent with thyrotoxicosis post-IRT, we recommend the 
measurement of TRAb and/or radionuclide scintigraphy to distinguish between GD 
and destructive thyroiditis (Fig. 2A); ultrasonography with color-flow or power 
Doppler examination can also be considered
1, ∅∅∅○
12. When should the treatment for 
abnormal thyroid function be commenced?
12a. We recommend to promptly initiate treatment if the patient is symptomatic or at 
high risk (pregnancy, cardiovascular disease), or if TD persists >3 months
1, ∅∅○○
12b. In the other cases, we suggest to delay treatment by 3 months to determine if the 
TD spontaneously resolves, or the thyroid function fluctuates
2, ∅○○○
13. What is the management of post-IRT 
GD? (Fig. 2a)
13a. We recommend treating patients with persistent hyperthyroidism and/or 
symptomatic GD with for 12–18 consecutive months as first-line treatment
1, ∅∅∅○
13b. We suggest consideration of a block and replace regimen (high-dose ATD with 
replacement LT4) for a better control of GD with fluctuating thyroid status (variability 
in thyroid status unexplained by changes in ATD)
2, ∅○○○
13c. We suggest consideration of RAI and surgery for hyperthyroid GD in cases of 
relapsing disease, drug intolerability, patient preference, or uncontrolled fluctuating 
disease course (variability in thyroid status unexplained by changes in ATD)
2, ∅○○○ 
14. How should post-IRT hypothyroidism 
be further investigated?
14. We recommend measurement of both TPOAb and TRAb antibodies in patients 
who develop hypothyroidism following IRT, using TRAb assays not influenced by high 
TSH levels
1, ∅∅○○
15. How should post-IRT hypothyroidism 
be managed? (Fig. 2b)
15a. We recommend commencing LT4 in patients with overt hypothyroidism 1, ∅∅∅○
15b. We recommend commencing LT4 in cases of mild (subclinical) and persistent (>3 
months) hypothyroidism with symptoms
1, ∅○○○
15c. We recommend monitoring TSH and FT4 every 3 months for the first year after 
thyroxine initiation in cases of negative TRAb, then as per local hypothyroidism 
guidelines
1, ∅○○○
15d. We suggest monitoring TSH and FT4 every month during 6 months after LT4 
initiation in cases of positive TRAb, then every 3 months; if stable, can be monitored as 
per local hypothyroidism guidelines
2, ∅○○○
15e. We suggest to manage hypothyroidism with positive TRAb in a specialist setting, 
or refer to an endocrinologist if thyrotoxicosis develop
2, ∅○○○
15f. We suggest a trial off LT4 after 12 months to determine if hypothyroidism post-
IRT has resolved, especially in hypothyroid cases with positive TRAb, hypothyroidism 
preceded by thyrotoxicosis or a daily LT4 dose ≤50 µg
2, ∅○○○
15g. We recommend to continue LT4 and keep TSH in the normal range as per ETA 
[83] and ATA [84] guidelines in case of women with post-IRT hypothyroidism seeking 
pregnancy, postponing the trial off LT4 until after delivery and breastfeeding
1, ∅∅∅○
16. How should post-IRT thyroiditis be 
managed?
16. We recommend a conservative approach with only symptomatic support (beta 
blockade) of subjects with confirmed thyroiditis (see recommendation 11), but close 
follow-up as other forms of TD may develop; treatment with steroids could be 
considered in cases of severe neck pain or severe thyrotoxicosis
1, ∅○○○
17. How should post-IRT GO be managed? 17a. We recommend advising IRT patients to alert the medical team if they develop 
signs and symptoms of GO, such as proptosis, diplopia, orbital inflammation
1, ∅∅○○
17b. We suggest managing GO post-IRT in the same way as spontaneous disease [90]; 
in MS patients a careful drug history is required, since they might be already on steroid 
treatment
2, ∅○○○
IRT, immune reconstitution therapy; TSH, thyroid-stimulating hormone; FT4, free-thyroxine; FT3, free-triiodothyronine; TD, thyroid dysfunction; GD, 
Graves’ disease; TPOAb, autoantibodies to thyroid peroxidase; TRAb, thyrotropin autoantibodies; HAART, highly active antiretroviral therapy; HIV, hu-
man immunodeficiency virus; BMT/HSCT, bone-marrow/hematopoietic-stem-cell transplantation; ATD, antithyroid drug; LT4, levothyroxine; GO, Graves’ 
orbitopathy.
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5. How Frequently Should Thyroid Function Be Tested after 
IRT?
Considering the high incidence of TD, the European Public 
Assessment Report of the European Medicines Agency about 
Lemtrada’s use in MS patients recommends testing thyroid func-
tion every 3 months for 4 years after the last alemtuzumab dose 
[54].
TD following HAART is less common and relates mostly to 
GD [15]. A cross-sectional study reported a higher TD preva-
lence (34%) among HIV-infected adults; however, it could be 
partially attributed to non-thyroidal or pituitary disease (13% 
had low FT4, either isolated or with low TSH; 1% had isolated 
raised FT4); the majority of the remainder had overt or subclini-
cal hypothyroidism [55]. The Infectious Diseases Society of 
America does not recommend regular thyroid function testing in 
HIV patients [56].
There is no universal agreement on timing of thyroid function 
monitoring after allogeneic BMT/HSCT, ranging from 3–6 months 
[22] to 1 year [42], and current lack of standardized guidelines for 
long-term follow-up of BMT/HSCT survivors, also susceptible to 
many additional compliances other than TD [42].
Recommendations
5a. Following alemtuzumab, we recommend instituting bio-
chemical follow-up with TSH testing every 3 months (Fig. 1). Time 
points should not be missed, as TD can develop rapidly; therefore, 
efforts should be made to ensure patients do not miss appoint-
ments (1, ∅∅○○).
5b. We recommend advising IRT patients to alert the medical 
team if they develop signs and symptoms of TD, such as, excessive 
sweating, unexplained weight loss or gain, nervousness, tachycar-
dia, and worsening tiredness (1, ∅∅○○).
5c. We do not recommend routine TSH monitoring following 
HAART in HIV patients; TSH measurement should be performed 
if TD is suspected on clinical grounds (1, ∅∅○○).
5d. We suggest to manage the long-term follow-up of patients 
after BMT/HSCT within a dedicated specialized setting (2, 
∅○○○).
6. For How Long post-IRT Routine Thyroid Function Testing 
Should Be Performed?
The TD onset has been described 32 months (average) or 16–23 
months (range 2–107 months) after the first and last alemtuzumab 
treatment for MS, respectively [12–14], with frequent episodes of 
transient autoimmune thyroiditis reported 6–12 months before 
GD onset (panel member’s personal experience). In the extension 
studies of alemtuzumab for MS (5 years follow-up), TD peaked at 
year 3, declining thereafter [57, 58]. However, late cases (rarely) of 
TD have been reported up to 9 years after the last alemtuzumab 
dose [12]. The European Medicines Agency’s Lemtrada-European 
Public Assessment Report recommends testing thyroid function 
every 3 months for 4 years after the last alemtuzumab dose [54].
Among HIV patients GD occurred 8–33 months (mean 17 
months) after HAART initiation [15–21].
Recommendations
6a. We recommend routine 3 monthly measuring of thyroid 
function to be continued for 4 years from the LAST alemtuzumab 
treatment (Fig. 1; 1, ∅∅○○).
6b. After this period, testing should be performed based on 
symptoms and signs suggestive of TD (1, ∅∅○○).
7. Should Thyroid Autoantibodies Be Measured in Euthyroid 
Individuals during Routine Monitoring for TD following IRT?
Although TRAb and TPOAb became positive during post-
alemtuzumab surveillance, not all of these patients developed TD, 
so the significance of positive antibodies in such asymptomatic, 
euthyroid individuals is unclear [13]. Similarly, a number of pa-
tients developed TD but remained antibody negative [12, 13]. 
Hence, at present, there is insufficient evidence to determine 
whether knowledge of antibody status during surveillance would 
inform or alter the frequency of thyroid function testing in alem-
tuzumab-treated patients.
TRAb and TPOAb became positive only 3–4 months (median) 
before the TD onset following HAART in a small patient cohort 
[17]; therefore, the detection of preclinical disease would not alter 
the monitoring or management of TD.
Most recent 
dose alemtuzumab
TSG at baseline Year 1 Year 2 Year 3 Year 4 Year ≥5
For 4 years following last cycle: TSH every 3 months TSH if thyroid
symptoms develop
Fig. 1. Following alemtuzumab, we recommend instituting biochemical follow-up with TSH testing every 3 
months. Moreover, we recommend routine 3 monthly measuring of thyroid function to be continued for 4 years 
from the LAST alemtuzumab treatment. TSH, thyroid-stimulating hormone.
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Recommendation
7. We do not recommend routine measurement of thyroid au-
toantibodies in euthyroid patients during surveillance (1,∅○○○).
8. Should Patients Be Routinely Screened with Thyroid 
Imaging post IRT?
In the phase III clinical trials comparing alemtuzumab with 
interferon β-1a in highly active MS, no overall increase in malig-
nancy was observed; however, papillary thyroid cancer was discov-
ered in 0.4% of alemtuzumab-treated patients [59, 60]. Such fre-
quency may have been influenced by ascertainment bias during the 
alemtuzumab clinical development program [61, 62]. In the 5-year 
follow-up extension studies, no increase in thyroid cancer was ob-
served [57, 58]. 
Before HAART, HIV patients due to immunodeficiency are at 
increased risk for opportunistic infectious thyroid disease (sub-
acute thyroiditis or rarely suppurative thyroiditis) that usually is 
part of a disseminated infection (e.g., by mycobacterium tubercu-
losis/avium, CMV, cryptococcus, pneumocystis) [63]. Infectious 
thyroiditis rarely causes a clinical TD, but when this occurs thyroid 
ultrasound and fine-needle aspiration cytology are indicated. HIV 
patients are also at increased risk for malignancy with potential 
localization in the thyroid, especially Kaposi sarcoma and lym-
phoma [64, 65]. In the post-HAART era, a decrease is observed in 
AIDS-associated cancers, but an increase is seen in other cancer 
types such as lung cancer and cervix carcinoma [66, 67].
Overall, there is no evidence for an increased risk of thyroid 
malignancy after IRT. Due to the high prevalence of thyroid nod-
ules in the population and the very low risk of thyroid cancer, rou-
tine thyroid US in the context of IRT is not indicated and carries 
the risk of overdiagnosis and subsequent overtreatment [68]. This 
does not to apply to cases where radiation therapy is also admin-
istered (i.e., BMT/HSCT) and is not the object of the present guide-
lines.
Recommendation
8. We do not recommend routine thyroid ultrasound or scin-
tigraphy post IRT (1,∅∅∅○).
9. When Should Patients with post-IRT TD Be Referred to an 
Endocrinologist?
Post-IRT TD might follow an atypical fluctuating course, ne-
cessitating appropriate diagnostic and therapeutic management 
[69]. Clinical symptoms can take up to 3 months to develop fol-
lowing biochemical TD. As a result, routine monitoring of thyroid 
function may mean that biochemical abnormalities are detected in 
the absence of clinical symptoms.
Among all cases of post-IRT TD, those triggered by alemtu-
zumab are the most common and better evaluated, therefore al-
lowing to design algorithms for its clinical management, as previ-
ously published in 2018 [70]. Here we provide an updated version 
of such algorithm (Fig. 2), including the importance of TRAb mea-
surement in hypothyroid cases and alerting clinicians about the 
possibility of fluctuating disease course in GD.
Recommendations
9a. We recommend referral to and review by an endocrinolo-
gist within 2–4 weeks in case of abnormal thyroid function con-
firmed on repeat testing, including asymptomatic cases (1, 
∅○○○).
9b. Depending on the local organization of clinical services, we 
suggest the use of a clinical thyroid management algorithm devel-
oped for nonspecialist physicians and based on alemtuzumab-in-
duced TD (Fig.  2). However, this should be combined with the 
availability of an endocrinologist in case of urgent thyroid-related 
problems or a complicated disease course (2, ∅○○○).
10. What Are the Recommendations for Pregnant Patients or 
Patients Planning Pregnancy?
The maternal gestational thyroid function has a crucial impact 
on pregnancy, fetal, and neonatal outcomes; therefore, TD occur-
ring during pregnancy, especially if overt, require a prompt cor-
rection [71, 72].
Recommendations
10a. We suggest that the thyroid function of women pregnant 
or seeking pregnancy within 4 years of last IRT should be moni-
tored more frequently (i.e., monthly; 2, ∅○○○).
10b. According to local resources and services, we suggest that 
these women should be immediately referred to an endocrinolo-
gist as soon as they develop TD, to be commenced on appropriate 
thyroid treatment and monitoring during pregnancy in a specialist 
setting (2, ∅○○○).
11. What Investigation Should Be Performed in Patients Found 
to Have post-IRT Biochemical Thyrotoxicosis?
The possible causes of post-IRT thyrotoxicosis are GD or de-
structive thyroiditis; other causes are unlikely in individuals who 
had persistently normal thyroid function before IRT [12, 13]. 
It is important to distinguish between these etiologies, since 
treatment will differ. Around 85–100% of patients with alemtu-
zumab-induced GD have positive TRAb [12, 13]. In cases where 
TRAb is negative or not available, thyroid scintigraphy will distin-
guish between GD (diffusely increased uptake) and destructive 
thyroiditis (reduced uptake) [73]; however, radionuclide uptake is 
not routinely reported in IRT literature [12, 13]. Ultrasonography 
with color-flow or power Doppler examination can also be consid-
ered to assess the intrathyroidal vascularity and the superior thy-
roid artery peak systolic velocity, usually both increased in GD 
[74–76].
Recommendation (Fig. 2a)
11. If biochemistry is consistent with thyrotoxicosis post-IRT, 
we recommend the measurement of TRAb and/or radionuclide 
scintigraphy to distinguish between GD and destructive thyroid-
itis. Ultrasonography with color-flow or power Doppler examina-
tion can also be considered (1, ∅∅∅○).
12. When Should the Treatment for Abnormal Thyroid 
Function Be Commenced?
Around 20% of patients with confirmed TD post-alemtuzumab 
have a fluctuating course or only transient dysfunction (< 3–6 
months) [12, 13, 37]. Hence, close monitoring (monthly thyroid 
function) before commencing treatment is advised.
Recommendations
12a. We recommend to promptly initiate treatment if the pa-
tient is symptomatic or at high risk (pregnancy, cardiovascular dis-
ease), or if TD persists > 3 months (1, ∅∅○○).
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Finding of abnormal TSH
on repeat testing
Finding of abnormal TSH
on repeat testing
Reduced 
uptake, suggesting
thyroiditis
TSH suppressed
TSH elevated
Measure FT4, FT3 and TRAb
Measure FT4, TPOAb and TRAb
TRAb positive, diagnose GD
TRAb positive, 
(risk of later thyrotoxicosis)
Monitor TSH/FT4 every 3 months
for the first year, then as per local
hypothyrodism guidelines
After 12 months: trial of LT4 dose tapering
(excluded women pregnant or 
seeking pregnancy)
Monitor TSH/FT4 monthly for the first 6 months,
then every 3 months; if stable, as per local hypothyroidism guidelines.
Ideally manage in a specialist setting,
or refer to an endocrinologist if thyrotoxicosis develops
Consider definitive treatment 
(RAI or total thyroidectomy) if frequent 
fluctuations in thyroid status
Consider RAI or total thyroidectomy
TRAb negative
TRAb negative
Thyroid scintigraphy scan
TSH elevated
TSH suppressed
See panel b
See panel a
Increased bilateral
symmetrical uptake, 
suggesting GD
Conservative treatment;
symptomatic support 
(beta blockade) if needed
Patchy increased 
uptake, suggesting toxic
goitre or adenoma After 12–18 monthstrial off ATD and 
monitor for relapse
Remain euthyroid
(remission)
Treat as per local
guidelines Abnormal thyroid 
function (relapse)
ATD not tolerated, 
patient preference, 
uncontrolled fluctuating course
Commence trial of ATD after 3 months
(excluding patients symptomatic and/or a high risk).
Fluctuating course: consider block and replace
Commence LT4 if overt hypothyroidism, or subclinical
and persistent (>3 months) and/or with symptoms
Hyperthyroidism/thyrotoxicosis
Hypothyroidism
a
b
Fig. 2. a Hyperthyroidism/thyrotoxicosis. b Hypothyroidism. TSH, thyroid-stimulating hormone; TRAb, thyrotropin receptor autoan-
tibodies; FT4, free-thyroxine; FT3, free-triiodothyronine; GD, Graves’ disease; ATD, antithyroid drug; RAI, radioiodine; TPOAb, auto-
antibodies to thyroid peroxidase; LT4, levothyroxine.
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12b. In the other cases, we suggest to delay treatment by 3 
months to determine if the TD spontaneously resolves, or the thy-
roid function fluctuates (2, ∅○○○).
13. What Is the Management of post-IRT GD?
Few studies have reported the type of treatment used and re-
sponse to therapy in alemtuzumab-induced GD. In the studies that 
have, most patients responded to antithyroid drugs (ATDs) [12–
14, 50, 77], at least initially.
Approximately one-third of patients with subclinical hyperthy-
roidism due to spontaneous GD undergo spontaneous resolution 
[78]; similarly, some studies have reported spontaneous resolution 
of post-IRT GD in 20% of cases [13], while others did not [12, 77]. 
This difference may be related to differences in the definition of TD: 
persistent for ≥3 months in Pariani et al. [12] versus present on one 
occasion in Daniels et al. [13]. In addition, subclinical disease is 
described as a frequent occurrence in one series; subclinical hypo-
thyroidism constituted 23% of hypothyroidism, with 1 of 7 patients 
requiring levothyroxine (LT4) treatment; 19% of GD was subclini-
cal with 4 out of 11 requiring ATD [13]. Other studies either did 
not distinguish between subclinical and clinical disease or did not 
observe it [12]. Of note, a patient subset (30%) experienced numer-
ous TD episodes post-alemtuzumab [13]; of these, 86% (19/22) had 
GD; 2 of the remainder had positive TRAb. Another study showed 
that 19% of GD patients displayed a fluctuating disease course, with 
sudden and unexpected changes from thyrotoxicosis to hypothy-
roidism and vice versa [79]: the presence of both blocking and stim-
ulating TRAb was demonstrated in a subset of these [12].
The literature is contradictory in terms of the relapse rates and 
requirements for definitive treatment in alemtuzumab-induced 
GD, with the lowest long-term remission rate being 34% [12]. In 
1999, Coles et al. [50] reported 7/9 (78%) patients relapsed after 
a course of block and replace therapy; 4 had subsequent RAI 
treatment, 1 thyroidectomy, and 2 a second course of ATD. Pari-
ani et al. [12] reported a high requirement (64%) for long-term 
ATD, RAI or surgery, compared with approximately 50% in con-
ventional GD [80]. In contrast, requirements for RAI or surgery 
were lower than expected in conventional GD in some reports; 
14% [14], 27% [77]. Given the uncertainty regarding response to 
treatment, it is reasonable to use definitive treatments for IRT-
induced GD in situations similar to that of conventional GD; cas-
es with fluctuating thyroid function may require a different ap-
proach.
The majority of post-HAART GD responds to ATD [20, 21], 
with a small number of patients requiring definitive treatment. 
Long-term relapse rates are not reported.
Recommendations (Fig. 2a)
13a. We recommend treating patients with persistent hyper-
thyroidism and/or symptomatic GD with ATD for 12–18 consecu-
tive months as first-line treatment (1, ∅∅∅○).
13b. We suggest consideration of a block and replace regimen 
(high-dose ATD with replacement LT4) for a better control of GD 
with fluctuating thyroid status (variability in thyroid status unex-
plained by changes in ATD; 2, ∅○○○).
13c. We suggest consideration of RAI and surgery for hyper-
thyroid GD in cases of relapsing disease, drug intolerability, pa-
tient preference, or uncontrolled fluctuating disease course (vari-
ability in thyroid status unexplained by changes in ATD; 2, 
∅○○○).
14. How Should post-IRT Hypothyroidism Be Further 
Investigated?
Development of subclinical (normal FT4), or overt (low FT4) 
hypothyroidism, is heralded by increased TSH levels. Hypothy-
roidism accounts for approximately 20–34% of post-alemtuzumab 
TD and is associated with positivity of thyroid autoantibodies in 
the majority of cases (TPOAb alone in 1/3, TRAb and/or TPOAb 
in 2/3) [12, 13].
TRAb with blocking activity on TSHR (TBAb) are responsible 
for around 30–50% of all hypothyroid cases [37]. Patients who ini-
tially present with hypothyroidism and positive TRAb can later 
develop thyrotoxicosis requiring ATD; these patients can exhibit 
fluctuating GD with unexpected changes from hypo- to hyperthy-
roidism and vice versa (19% of cases) [12]. Hence, TRAb measure-
ment in hypothyroid patients can identify those in whom a more 
intensive biochemical surveillance strategy is advised.
When measuring TRAb levels in hypothyroid patients, it is im-
portant to exclude false-positive cases due to high TSH levels. 
Some of the most widely used commercial kits (Brahms Lumitest, 
Brahms RIA, Roche Elecsys, RSR-Coated tube RIA, RSR 3rd Gen 
ELISA, Siemens Immulite) did not show any cross reactivity with 
high levels of TSH (i.e., > 140 mU/L), as reported in their technical 
information sheets.
The phenomenon of fluctuating GD or TRAb-positive hypo-
thyroidism has not been reported following HAART, but has been 
seen following alemtuzumab administration for vasculitis (panel 
member’s personal experience).
Recommendation
14. We recommend measurement of both TPOAb and TRAb 
antibodies in patients who develop hypothyroidism following IRT, 
using TRAb assays not influenced by high TSH levels (1, ∅∅○○).
15. How Should post-IRT Hypothyroidism Be Managed?
When overt or clinical hypothyroidism develops, treatment 
with LT4 is indicated according to the general guidelines [81].
In contrast to the usually irreversible hypothyroidism of clas-
sical Hashimoto’s thyroiditis disease, a higher frequency of po-
tential reversibility needs to be considered in hypothyroidism de-
veloping post-IRT, as a higher frequency of atypical autoimmune 
thyroid disease is reported [69]. This finding is likely related to 
TRAb found positive in about 70% of hypothyroid cases [12, 13] 
and with described blocking activity (TBAb) [37]. TRAb mea-
surement should be considered in cases of post-IRT hypothy-
roidism; TRAb presence indicates potential later recovery from 
hypothyroidism since TBAb usually do not persist for a long time 
[79].
In HIV patients, usually hypothyroidism is not associated with 
TPOAb/TRAb positivity, suggesting a non-autoimmune patho-
physiology, that is, infectious thyroiditis [82].
Recommendations (Fig. 2b)
15a. We recommend commencing LT4 in patients with overt 
hypothyroidism (1, ∅∅∅○).
15b. We recommend commencing LT4 in cases of mild (sub-
clinical) and persistent (> 3 months) hypothyroidism with symp-
toms (1, ∅○○○).
15c. We recommend monitoring TSH and FT4 every 3 months 
for the first year after LT4 initiation in cases of negative TRAb, 
then as per local hypothyroidism guidelines (1, ∅○○○).
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15d. We suggest monitoring TSH and FT4 every month during 
6 months after LT4 initiation in cases of positive TRAb, then every 
3 months. If stable, they can be monitored as per local hypothy-
roidism guidelines (2, ∅○○○).
15e. We suggest to manage hypothyroidism with positive 
TRAb in a specialist setting or refer to an endocrinologist if thyro-
toxicosis develop (2, ∅○○○).
15f. We suggest a trial off LT4 after 12 months to determine if 
hypothyroidism post-IRT has resolved, especially in hypothyroid 
cases with positive TRAb, hypothyroidism preceded by thyrotoxi-
cosis or a daily LT4 dose ≤50 µg (2, ∅○○○).
15g. We recommend to continue LT4 and keep TSH in the nor-
mal range as per ETA [83] and ATA [84] guidelines in case of 
women with post-IRT hypothyroidism seeking pregnancy, post-
poning the trial off LT4 until after delivery and breastfeeding (1, 
∅∅∅○).
16. How Should post-IRT Thyroiditis Be Managed?
Cases with a fluctuating TD course and negative TRAb were 
assumed to be thyroiditis – accounting for 5–10% of patients with 
post-alemtuzumab TD [12, 13]. In the series from Daniels et al. 
[13], one case developed GD after painless thyroiditis; another case 
developed hypothyroidism post-thyroiditis followed by another 
episode of painless thyroiditis.
No precise data about the prevalence of thyroiditis secondary 
to different IRT forms are available; hence, it is difficult to be cer-
tain of the etiology.
Recommendation
16. We recommend a conservative approach with only symp-
tomatic support (beta blockade) of subjects with confirmed thy-
roiditis (see recommendation 11), but close follow-up as other 
forms of TD may develop. Treatment with steroids could be con-
sidered in cases of severe neck pain or severe thyrotoxicosis (1, 
∅○○○).
17. How Should post-IRT Graves’ Orbitopathy Be Managed?
In spontaneous GD, some degree of ocular involvement has 
been reported in about 30–50% of cases [85, 86]. In particular, 
mild-inactive and moderate-to-very-severe Graves’ orbitopathy 
(GO) is present in about 20% and 5–6% of GD patients, respec-
tively [87, 88]. Less data are available regarding the GO prevalence 
among patients with post-IRT GD. A recent study described a 13% 
GO prevalence among 52 post-alemtuzumab GD patients, partic-
ularly severe in 2 cases (both non-smokers), and possibly linked to 
RAI treatment without steroid cover in one individual [12].
A GO-focused cross-sectional study identified 3/11 (27%) pa-
tients with HIV/HAART-induced GD developing GO, character-
ized by different EUGOGO severity: 1 mild, 1 moderate-severe, 1 
sight threatening [89]. There is no evidence suggesting that the 
clinical management of GO in post-IRT GD should be different 
from the spontaneous form [90]. The clinical management of GO 
in HIV patients involves additional challenges, since HAART con-
flicts with ATD, immunosuppressive treatments and analgesics for 
orbital decompression surgery often used in GO treatment [89].
Recommendations
17a. We recommend advising IRT patients to alert the medical 
team if they develop signs and symptoms of GO, such as proptosis, 
diplopia, orbital inflammation (1, ∅∅○○).
17b. We suggest managing GO post-IRT in the same way as 
spontaneous disease [90]. In MS patients, a careful drug history is 
required, since they might be already on steroid treatment (2, 
∅○○○).
Discussion and Future Developments
The present guidelines provide recommendations and 
suggestions for the clinical management of TD of autoim-
mune etiology triggered by IRT. The commonest cause is 
alemtuzumab treatment of individuals with active relaps-
ing remitting MS, followed by HAART treatment in HIV 
patients. For this reason, we have tailored our clinical al-
gorithm toward alemtuzumab-induced thyroid disor-
ders, highlighting the differences with the spontaneous 
form and guiding the clinician through key examinations 
for correct diagnosis and appropriate clinical manage-
ment. Less commonly, TD occurs after BMT/HSCT; 
however, as different mechanisms of radiation-induced 
thyroid damage are also involved in the development of 
TD, it does not represent a central topic for these guide-
lines.
The prevalence of TD post-alemtuzumab is likely to 
increase in the near future since alemtuzumab was only 
licensed for MS in 2013, and thyroid complications are a 
delayed adverse effect of treatment. However, efforts are 
being made to mitigate the autoimmunity induced by 
alemtuzumab, and a wider spectrum of effective treat-
ments for MS are being developed (including but not lim-
ited to ocrelizumab, cladribine, opicinumab), which ap-
pear not to be associated with autoimmunity (although 
have their own set of side effects) [91–93]. Hence, in the 
longer term, rates of TD associated with alemtuzumab 
may fall. Similarly, during the past 20 years, the rate of 
new HIV infections has been stably decreasing worldwide 
[94], so that we might also expect decreasing frequency of 
thyroid complications related to HAART therapy. How-
ever, alternative novel therapies are also being developed 
that act on T and B cell compartments simultaneously 
followed by repopulation, which may also be associated 
with induced autoimmune disorders.
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